Table 2 Patient characteristics
Ethiopia | Indonesia | Kazakhstan | ||||
|---|---|---|---|---|---|---|
n | (%) | n | (%) | n | (%) | |
Patient group | ||||||
Intensive phase of standard (re)treatment regimen | 12 | (6.2) | 62 | (23.8) | 41 | (27.3) |
Continuation phase of standard (re)treatment regimen | 13 | (6.7) | 56 | (21.5) | 13 | (8.7) |
Just diagnosed with MDR-TB | 21 | (10.8) | 29 | (11.1) | 2 | (1.3) |
Intensive phase of MDR-TB treatment | 85 | (43.8) | 55 | (21.1) | 62 | (41.3) |
Continuation phase of MDR-TB treatment | 63 | (32.5) | 59 | (22.6) | 32 | (21.3) |
Type of TB | ||||||
Pulmonary smear positive | 176 | (91.2) | 166 | (63.6) | 121 | (80.7) |
Pulmonary smear negative | 4 | (2.1) | 72 | (27.6) | 27 | (18.0) |
Extrapulmonary | 13 | (6.7) | 16 | (6.1) | 2 | (1.3) |
No information | 1 | (0.5) | 7 | (2.7) | 0 | (0.0) |
Gender | ||||||
Male | 107 | (55.2) | 138 | (52.9) | 100 | (66.7) |
Female | 87 | (44.8) | 120 | (46.0) | 50 | (33.3) |
No information | 3 | (1.2) | ||||
Age (years) | ||||||
21–29 | 110 | (56.7) | 62 | (23.8) | 47 | (31.3) |
30–39 | 49 | (25.3) | 71 | (27.2) | 43 | (28.7) |
40–49 | 20 | (10.3) | 66 | (25.3) | 42 | (28.0) |
50+ | 15 | (7.7) | 61 | (23.4) | 18 | (12.0) |
No information | 1 | (0.4) | ||||
HIV | ||||||
Positive | 41 | (21.1) | 8 | (3.1) | 0 | (0.0) |
Negative | 146 | (75.3) | 128 | (49.0) | 150 | (100) |
not tested/unknown | 7 | (3.6) | 125 | (47.9) | 0 | (0.0) |